PhytoFoundry Cultivates Bioactives with Plant Cell Tech

A new UK-based venture, PhytoFoundry, is emerging from its development phase with a novel approach to producing high-value compounds. Leveraging advanced plant cell culture techniques, the company aims to address critical supply chain and purity challenges in the premium ingredients market, initially focusing on the cosmetics sector. This strategic pivot is informed by the founder's prior experience, seeking to build a more capital-efficient and commercially-driven enterprise from its inception.

The company's inaugural target is bakuchiol, a sought-after skincare ingredient derived from the babchi plant, often positioned as a natural alternative to retinol. Traditional extraction methods for bakuchiol can be complex, leading to difficulties in isolating the desired molecule while simultaneously removing allergenic compounds. PhytoFoundry's proprietary cell culture platform is designed to precisely guide cellular metabolism, enhancing the yield of target bioactives and simplifying downstream purification processes, thereby offering a cleaner, more consistent product.

Samuel Casasola Zamora, PhD, founder of PhytoFoundry, highlighted the crucial lessons learned from his previous venture, Green Bioactives. "We made significant strides in improving yield and productivity, but the timing for those breakthroughs proved challenging," he stated. "This time, our strategy is fundamentally commercial from the outset, prioritizing product-market fit, customer validation, and inherent capital efficiency." This focus aims to mitigate the funding hurdles that impacted earlier ventures in the space.

The market for bakuchiol and similar high-value bioactives is substantial, with the broader retinol market estimated to be worth between $1.2 billion and $2 billion globally. By targeting ingredients with premium pricing and lower regulatory entry barriers, PhytoFoundry seeks to establish a strong economic foundation before potentially expanding into more price-sensitive segments like food and crop protection. Early discussions include a letter of intent from an ingredient manufacturer seeking a more reliable source of purified bakuchiol.

Chris Meaney, a former executive at Green Bioactives, is supporting PhytoFoundry on a fractional basis, contributing to its commercial strategy and fundraising efforts. He emphasized the importance of a focused product pipeline. "It's easy to get captivated by the science, but we learned the necessity of concentrating on products with clear commercial viability from day one," Meaney commented. "Working on too many fronts with a lean team can dilute focus and impact." This disciplined approach is central to PhytoFoundry's operational philosophy.

Scaling plant cell culture economically presents unique technical hurdles compared to microbial fermentation, including slower growth rates, shear sensitivity, and cell clumping. PhytoFoundry is addressing these by prioritizing the selection of robust cell lines and developing sophisticated cell banking strategies to ensure consistent productivity across batches. Furthermore, the company plans to leverage existing fermentation infrastructure where feasible and is exploring AI-driven data analysis to optimize experimental design and accelerate development cycles. The venture has secured HMRC Advance Assurance, indicating its fundraising activities are likely to qualify for UK tax incentives.